 Adagio Therapeutics Inc NASDAQ: ADGI is trading higher Wednesday after the company announced its investigational drug adintrevimab ADG20 was the first monoclonal antibody to meet primary endpoints with statistical significance across pre- and post-exposure prophylaxis and treatment. 